How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicardipine-esmolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nicardipine , Esmolol — Competitive Intelligence Brief

Nicardipine , Esmolol (Nicardipine , Esmolol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker + Beta-1 selective adrenergic antagonist combination. Area: Cardiovascular.

marketed Calcium channel blocker + Beta-1 selective adrenergic antagonist combination L-type calcium channels; Beta-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Nicardipine , Esmolol (Nicardipine , Esmolol) — Nanjing Medical University. This is a combination of nicardipine (a calcium channel blocker) and esmolol (a beta-1 selective adrenergic antagonist) that work synergistically to reduce blood pressure and heart rate through different pathways.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicardipine , Esmolol TARGET	Nicardipine , Esmolol	Nanjing Medical University	marketed	Calcium channel blocker + Beta-1 selective adrenergic antagonist combination	L-type calcium channels; Beta-1 adrenergic receptor
Nitrendipine/Atenolol	Nitrendipine/Atenolol	Shanghai Jiao Tong University School of Medicine	marketed	Calcium channel blocker / Beta-blocker combination	L-type calcium channels; Beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker + Beta-1 selective adrenergic antagonist combination class)

Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nicardipine , Esmolol — Competitive Intelligence Brief. https://druglandscape.com/ci/nicardipine-esmolol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab